Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results-Reference-Cited by-同舟云学术

Ibrutinib alone or with dexamethasone for relapsed or relapsed and refractory multiple myeloma: phase 2 trial results

Published:2018-02-13 Issue:6 Volume:180 Page:821-830
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Richardson Paul G.¹^ORCID,Bensinger William I.²,Huff Carol Ann³,Costello Caitlin L.⁴,Lendvai Nikoletta⁵,Berdeja Jesus G.⁶,Anderson Larry D.⁷^ORCID,Siegel David S.⁸,Lebovic Daniel⁹,Jagannath Sundar¹⁰,Laubach Jacob P.¹¹^ORCID,Stockerl-Goldstein Keith E.¹²,Kwei Long¹³,Clow Fong¹³,Elias Laurence¹³,Salman Zeena¹³,Graef Thorsten¹³,Bilotti Elizabeth¹³,Vij Ravi¹²

Affiliation:

1. Department of Medical Oncology; Dana-Farber Cancer Institute; Boston MA USA

2. Clinical Research Division; Fred Hutchinson Cancer Research Center; Seattle WA USA

3. Department of Oncology; Johns Hopkins University; Baltimore MD USA

4. Division of Bone Marrow Transplantation; Moores Cancer Center; University of California San Diego; La Jolla CA USA

5. Memorial Sloan Kettering Cancer Center; New York NY USA

6. Myeloma Research; Sarah Cannon Research Institute; Nashville TN USA

7. Simmons Comprehensive Cancer Center; University of Texas Southwestern Medical Center; Dallas TX USA

8. John Theurer Cancer Center; Hackensack University Medical Center; Hackensack NJ USA

9. Hematology and Medical Oncology; Great Lakes Cancer Management Specialists; Grosse Pointe Woods MI USA

10. Mount Sinai Medical Center; Tisch Cancer Institute; New York NY USA

11. Jerome Lipper Multiple Myeloma Center; Dana-Farber Cancer Institute; Boston MA USA

12. Department of Medicine; Washington University School of Medicine; St. Louis MO USA

13. Pharmacyclics LLC, an AbbVie Company; Sunnyvale CA USA

Funder

Pharmacyclics LLC, an AbbVie Company

National Institutes of Health

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.15058/fullpdf

Reference37 articles.

1. An essential role for Bruton's tyrosine kinase in the regulation of B-cell apoptosis;Anderson;Proceedings of the National Academy of Science U S A,1996

2. Clinically relevant end points and new drug approvals for myeloma;Anderson;Leukemia,2008

3. Role of Bruton's tyrosine kinase in myeloma cell migration and induction of bone disease;Bam;American Journal of Hematology,2013

4. Syndecan-1 (CD138) suppresses apoptosis in multiple myeloma by activating IGF1 receptor: prevention by synstatinIGF1R inhibits tumor growth;Beauvais;Cancer Research,2016

5. Promising therapies in multiple myeloma;Bianchi;Blood,2015

Cited by 34 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Research progress of the chemokine/chemokine receptor axes in the oncobiology of multiple myeloma (MM);Cell Communication and Signaling;2024-03-12

2. Recent Advances in the Applications of Small Molecules in the Treatment of Multiple Myeloma;International Journal of Molecular Sciences;2023-01-31

3. Beyond the cell: novel noncellular immunotherapy approaches to multiple myeloma;Hematology;2022-12-09

4. CXCL13 chemokine is a novel player in multiple myeloma osteolytic microenvironment, M2 macrophage polarization, and tumor progression;Journal of Hematology & Oncology;2022-10-10

5. BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies;Journal of Hematology & Oncology;2022-10-01